Moderate levels of 5-fluorocytosine cause the emergence of high frequency resistance in cryptococci.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
08 06 2021
Historique:
received: 19 01 2021
accepted: 14 05 2021
entrez: 9 6 2021
pubmed: 10 6 2021
medline: 16 6 2021
Statut: epublish

Résumé

The antifungal agent 5-fluorocytosine (5-FC) is used for the treatment of several mycoses, but is unsuitable for monotherapy due to the rapid development of resistance. Here, we show that cryptococci develop resistance to 5-FC at a high frequency when exposed to concentrations several fold above the minimal inhibitory concentration. The genomes of resistant clones contain alterations in genes relevant as well as irrelevant for 5-FC resistance, suggesting that 5-FC may be mutagenic at moderate concentrations. Mutations in FCY2 (encoding a known permease for 5-FC uptake), FCY1, FUR1, UXS1 (encoding an enzyme that converts UDP-glucuronic acid to UDP-xylose) and URA6 contribute to 5-FC resistance. The uxs1 mutants accumulate UDP-glucuronic acid, which appears to down-regulate expression of permease FCY2 and reduce cellular uptake of the drug. Additional mutations in genes known to be required for UDP-glucuronic acid synthesis (UGD1) or a transcriptional factor NRG1 suppress UDP-glucuronic acid accumulation and 5-FC resistance in the uxs1 mutants.

Identifiants

pubmed: 34103502
doi: 10.1038/s41467-021-23745-1
pii: 10.1038/s41467-021-23745-1
pmc: PMC8187385
doi:

Substances chimiques

Fungal Proteins 0
Uridine Diphosphate Glucuronic Acid 2616-64-0
Flucytosine D83282DT06

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3418

Références

Eukaryot Cell. 2006 Jul;5(7):1147-56
pubmed: 16835458
Biochemistry. 1968 May;7(5):1761-70
pubmed: 4297054
mBio. 2018 Dec 4;9(6):
pubmed: 30514783
Genome Res. 2016 Oct;26(10):1355-1362
pubmed: 27440870
Mol Microbiol. 2002 Aug;45(3):837-49
pubmed: 12139628
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14607-12
pubmed: 11717398
PLoS Genet. 2014 Apr 17;10(4):e1004261
pubmed: 24743168
Clin Infect Dis. 2014 May;58(9):1308-11
pubmed: 24585567
Rev Iberoam Micol. 2008 Jun;25(2):101-6
pubmed: 18473504
J Virol. 2012 Sep;86(18):9640-6
pubmed: 22740415
mBio. 2019 Aug 27;10(4):
pubmed: 31455652
Nature. 1959 Oct 17;184:1213-5
pubmed: 14403183
Med Mycol. 2018 Oct 1;56(7):857-867
pubmed: 29554336
Crit Rev Microbiol. 1987;15(1):45-56
pubmed: 3319420
Nat Commun. 2020 Jan 8;11(1):127
pubmed: 31913284
Eur J Biochem. 1973 Jan 15;32(2):276-82
pubmed: 4569075
Yeast. 2006 Jul 15;23(9):707-15
pubmed: 16845689
Am J Med. 1987 Aug;83(2):236-42
pubmed: 3303926
Antimicrob Agents Chemother. 2018 May 25;62(6):
pubmed: 29610197
FEMS Yeast Res. 2016 May;16(3):
pubmed: 26945893
mBio. 2011 Feb 08;2(1):e00342-10
pubmed: 21304167
Clin Microbiol Rev. 1999 Oct;12(4):501-17
pubmed: 10515900
Antimicrob Agents Chemother. 2010 Jun;54(6):2303-11
pubmed: 20385871
Science. 2006 Jul 21;313(5785):367-70
pubmed: 16857942
Annu Rev Microbiol. 1998;52:591-625
pubmed: 9891809
Antimicrob Agents Chemother. 2004 Nov;48(11):4377-86
pubmed: 15504867
Antimicrob Agents Chemother. 1999 Aug;43(8):1856-61
pubmed: 10428902
Clin Infect Dis. 2010 Feb 1;50(3):291-322
pubmed: 20047480
J Biol Chem. 2004 Dec 3;279(49):51669-76
pubmed: 15383535
Biochemistry. 1966 May;5(5):1625-32
pubmed: 5335810
Infect Immun. 2003 Sep;71(9):4831-41
pubmed: 12933823
Nature. 1956 Sep 8;178(4532):531-2
pubmed: 13358789
PLoS Comput Biol. 2016 Apr 21;12(4):e1004873
pubmed: 27100738
Antimicrob Agents Chemother. 2010 Nov;54(11):4733-8
pubmed: 20823283
PLoS One. 2015 Aug 12;10(8):e0135110
pubmed: 26267134
Cold Spring Harb Perspect Med. 2014 Jul 01;4(7):a019760
pubmed: 24985132
Eukaryot Cell. 2004 Dec;3(6):1601-8
pubmed: 15590833
Nucleic Acids Res. 2012 Jan;40(Database issue):D675-81
pubmed: 22064857
J Clin Invest. 2019 Mar 1;129(3):999-1014
pubmed: 30688656
Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4601-5
pubmed: 2052544
Biotechniques. 1993 Apr;14(4):538-40
pubmed: 8476589
Antimicrob Agents Chemother. 1983 Jan;23(1):79-85
pubmed: 6338821
Antimicrob Agents Chemother. 2018 Mar 27;62(4):
pubmed: 29378705
Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12003-8
pubmed: 11593010
Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17258-63
pubmed: 15572442
Metabolites. 2020 Mar 12;10(3):
pubmed: 32178468
PLoS Pathog. 2010 Apr 01;6(4):e1000848
pubmed: 20368972
Mol Gen Genet. 1986 Oct;205(1):74-81
pubmed: 3025561
Antimicrob Agents Chemother. 2007 Jan;51(1):369-71
pubmed: 17060521
J Mol Biol. 1969 Sep 14;44(2):363-75
pubmed: 4940922
Clin Infect Dis. 1998 Aug;27(2):260-4
pubmed: 9709874
Genome Biol. 2006;7(10):R100
pubmed: 17076895
Antimicrob Agents Chemother. 1973 Jun;3(6):649-56
pubmed: 4597734

Auteurs

Yun C Chang (YC)

Molecular Microbiology Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD, USA. ychang@niaid.nih.gov.

Ami Khanal Lamichhane (AK)

Molecular Microbiology Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD, USA.

Hongyi Cai (H)

Clinical Mass Spectrometry Core, NIDDK, NIH, Bethesda, MD, USA.

Peter J Walter (PJ)

Clinical Mass Spectrometry Core, NIDDK, NIH, Bethesda, MD, USA.

John E Bennett (JE)

Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD, USA.

Kyung J Kwon-Chung (KJ)

Molecular Microbiology Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD, USA.

Articles similaires

T-Lymphocytes, Regulatory Lung Neoplasms Proto-Oncogene Proteins p21(ras) Animals Humans

Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis.

Spencer D Shelton, Sara House, Luiza Martins Nascentes Melo et al.
1.00
DNA, Mitochondrial Humans Melanoma Mutation Neoplasm Metastasis

Prevalence and implications of fragile X premutation screening in Thailand.

Areerat Hnoonual, Sunita Kaewfai, Chanin Limwongse et al.
1.00
Humans Fragile X Mental Retardation Protein Thailand Male Female

Classifications MeSH